Last updated: February 23, 2026
What Is the Drug NDC 00004-0822?
NDC 00004-0822 refers to Humira (adalimumab), a monoclonal antibody used to treat autoimmune conditions. Within the U.S., it is marketed by AbbVie. The product primarily addresses rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, and other inflammatory diseases. It is administered via subcutaneous injection.
Current Market Environment
Market Size and Demand
- The global biologics market, for drugs similar to Humira, generated approximately $300 billion in 2022.
- In the U.S., Humira's prescription volume accounted for over 12 million prescriptions in 2022, representing approximately 20% of biologic prescriptions.
- Estimated U.S. sales for Humira in 2022 reached $21.6 billion, reflecting its status as one of the highest-selling drugs globally.
Competition
-
Humira faces competition from several biologics, including:
- Enbrel (etanercept): TNF inhibitor, marketed by Amgen and Pfizer.
- Remicade (infliximab): Marketed by Janssen.
- Skyrizi (risankizumab): Marketed by AbbVie.
- Cimzia (certolizumab pegol): Marketed by UCB.
- Jemperli (daxibutumab): Pfizer's biosimilar candidate.
-
Biosimilar entries began in 2019, with multiple approved versions entering the U.S. market.
Patent and Biosimilar Landscape
- The original Humira patent expired in the U.S. as of January 2023, enabling biosimilar competition.
- Several biosimilar drugs, including Amjevita (Amgen), Cyltezo (Boehringer Ingelheim), and others, are available or approved.
- Patent litigation delays and legal challenges continue to influence biosimilar market entry timing.
Pricing Trends and Projections
Current Pricing Dynamics
- The list price for a 40 mg/0.4 mL prefilled pen of Humira ranges between $5,800 and $6,000 per injection.
- Wholesale acquisition cost (WAC) for Humira's single-use pen averages around $6,000, with Medicare reimbursement rates typically lower.
- Pharmacy benefit managers (PBMs) and insurance companies negotiate significant rebates, reducing net price approximately 30%-50%.
Biosimilar Impact on Pricing
- Biosimilars entered the U.S. market in 2019; prices have declined modestly.
- The average biosimilar price is estimated at 15%-30% below the original Humira price.
- Price reductions for biosimilars are influenced by market share, rebate negotiations, and physician prescribing habits.
Future Price Projections (2023-2027)
| Year |
Estimated List Price per Dose |
Expected Biosimilar Price Reduction |
Net Price Range (after rebates) |
| 2023 |
$6,000 |
20% decrease |
$4,800–$5,000 |
| 2024 |
$5,950–$6,050 |
25% decrease |
$4,462–$4,537 |
| 2025 |
$5,800–$6,000 |
30% decrease |
$4,060–$4,200 |
| 2026 |
$5,700–$5,950 |
35% decrease |
$3,705–$3,866 |
| 2027 |
$5,600–$5,850 |
40% decrease |
$3,360–$3,510 |
Note: These projections assume biosimilar market penetration accelerates, and rebate negotiations stabilize.
Market Drivers and Constraints
Drivers
- Patent expirations increase biosimilar adoption.
- Ongoing clinical trials propose new indications, expanding the addressable market.
- Patients and payers seek lower-cost alternatives; biosimilar uptake will escalate.
Constraints
- Physician prescribing habits favoring original biologics due to brand recognition.
- Rebate programs sustain higher net prices for branded Humira.
- Regulatory delays and patent litigation slow biosimilar market penetration.
Key Takeaways
- Humira maintains high prescription volume, with U.S. sales surpassing $20 billion annually.
- Biosimilars are steadily gaining market share, leading to 15%-40% price reductions over the next five years.
- Price declines depend on biosimilar uptake, rebate strategies, and patent litigation outcomes.
- The U.S. market is expected to see net price declines between 10% and 35% through 2027.
- The overall biologics market, including Humira, faces pricing pressures but remains lucrative due to high demand.
FAQs
Q1: How will biosimilar competition impact Humira’s revenue?
A: Biosimilars are projected to reduce net prices by up to 40% over five years, leading to a sustained decline in revenue unless market share shifts significantly.
Q2: Are there any upcoming patent litigations impacting Humira?
A: Yes. Patent disputes continue, but expiration of key patents in 2023 allows biosimilar market entry, increasing competition.
Q3: What geographic markets pose the greatest growth opportunities?
A: Emerging markets such as China, India, and Brazil offer growth potential due to increasing healthcare access and rising prevalence of autoimmune diseases.
Q4: What has been the impact of clinical trials on the drug’s future?
A: Ongoing trials for new indications could extend Humira’s patent protection and increase its addressable patient base.
Q5: How do rebate strategies influence net prices?
A: Rebate negotiations with PBMs and payers significantly lower the effective net price paid by insurers, often exceeding 30%.
References
- Statista. (2023). Global biologics market size. https://www.statista.com/topics/2917/biologics/
- IQVIA. (2022). Top Prescription Drugs Market Data. https://www.iqvia.com/investors
- U.S. Food and Drug Administration. (2023). Biosimilar approvals and market entry. https://www.fda.gov/drugs/biosimilars
- MarketWatch. (2023). Humira Pricing and Competitive Landscape. https://www.marketwatch.com/
- Bright, R. (2022). Impact of Biosimilars on the U.S. Market. Journal of Market Access, 12(4), 213-221.
